The revolutionary drug, lenacapavir, will be available through a partnership between the Gates Foundation and Indian pharmaceutical manufacturer Hetero Labs,
The Global Fund plans to supply at least 2 million doses globally, primarily targeting sub-Saharan Africa where HIV incidence remains highest.